Metoprolol succinate and Relistor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Metoprolol succinate (metoprolol succinate) and Relistor (methylnaltrexone bromide). Common drug interactions include pain among females and arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Metoprolol succinate and Relistor. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Metoprolol succinate?

Metoprolol succinate has active ingredients of metoprolol succinate. It is often used in high blood pressure. eHealthMe is studying from 66,933 Metoprolol succinate users. Check the latest studies of Metoprolol succinate.

What is Relistor?

Relistor has active ingredients of methylnaltrexone bromide. eHealthMe is studying from 1,659 Relistor users. Check the latest studies of Relistor.



On Aug, 06, 2026

18 people who take Metoprolol succinate and Relistor together, and have interactions are studied.

Metoprolol succinate and Relistor drug interactions.

What are the common drug interactions of Metoprolol Succinate and Relistor, by gender? *:

female:

  1. Pain
  2. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  3. Aphasia (damage to the parts of the brain that control language)
  4. Blood sodium decreased
  5. Crying
  6. Gait disturbance
  7. Nausea (feeling of having an urge to vomit)
  8. Affect lability (emotional incontinence)
  9. Back pain
  10. Blood pressure fluctuation

male:

  1. Arthralgia (joint pain)
  2. Abdominal distension
  3. Back pain
  4. Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
  5. Benign prostatic hyperplasia (benign enlargement of the prostate)
  6. Bone disorder
  7. Bone pain
  8. Cardiac disorder
  9. Cerebral small vessel ischaemic disease (inadequate blood supply to small blood vessel of brain)
  10. Chest pain

What are the common drug interactions of Metoprolol Succinate and Relistor, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Constipation
  2. Diarrhoea
  3. Dizziness
  4. Dry mouth
  5. Ear infection
  6. Eye swelling
  7. Flushing (the warm, red condition of human skin)
  8. Nausea (feeling of having an urge to vomit)
  9. Pain
  10. Vomiting

50-59:

  1. Mouth ulceration (mouth ulcers)
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Myopia (difficult to see objects that are far away)
  4. Nasal obstruction (blockage of nose)
  5. Nasal septum deviation (deviated nasal septum)
  6. Nasal turbinate hypertrophy (nasal turbinates become enlarged)
  7. Neoplasm malignant (cancer tumour)
  8. Neoplasm progression (growth of tumour)
  9. Nephrolithiasis (calculi in the kidneys)
  10. Neuralgia (pain in one or more nerves)

60+:

  1. Fall
  2. Abdominal pain
  3. Decreased appetite
  4. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  5. Dyspnoea (difficult or laboured respiration)
  6. Escherichia bacteraemia (presence of bacteria escherichia coli in the blood)
  7. Faeces discoloured
  8. Failure to thrive (inadequate weight gain and physical growth in children)
  9. Fungal infection
  10. Generalised oedema (swelling all over the body)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 9 people, 50.00%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 8 people, 44.44%
  3. Multiple Myeloma (cancer of the plasma cells): 2 people, 11.11%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.56%
  5. Pancreatic Carcinoma (pancreatic cancer): 1 person, 5.56%
  6. Ovarian Cancer (cancer of ovary): 1 person, 5.56%
  7. Metastases To Bone (cancer spreads to bone): 1 person, 5.56%
  8. Gout (uric acid crystals building up in the body): 1 person, 5.56%
  9. Dyslipidaemia (abnormal amount of lipids): 1 person, 5.56%
  10. Drowsiness: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Metoprolol succinate and Relistor?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Metoprolol succinate and Relistor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Metoprolol succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Relistor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Metoprolol succinate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Relistor and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol succinate and methylnaltrexone bromide (the active ingredients of Metoprolol succinate and Relistor, respectively), and Metoprolol succinate and Relistor (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: